

ForPatients

by Roche

Idiopathic Pulmonary Fibrosis (IPF)

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension

Trial Status
Completed

Trial Runs In
13 Countries

Trial Identifier
NCT02951429 2015-005131-40
MA29957

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IIb, randomized, placebo-controlled, multicenter, international study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone (Esbriet) treatment in participants with advanced IPF and intermediate or high probability of Group 3 pulmonary hypertension (PH) who are on a stable dose of pirfenidone with demonstrated tolerability. Participants will be randomized to receive 1 year of treatment with either oral sildenafil or matching placebo while continuing to take pirfenidone.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02951429 2015-005131-40 MA29957
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 40 Years & <= 80 Years

Healthy Volunteers
No
